| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 10/02/2001 | US6297277 Cysteine protease inhibitors containing heterocyclic leaving groups |
| 10/02/2001 | US6297266 Inhibit the binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. |
| 10/02/2001 | US6297261 Potent chloride channel blockers; treatment of sickle cell anemia, brain edema following ischaemia or tumors, diarrhea, hypertension (diuretic), osteoporosis, and for the reduction of the intraocular pressure |
| 10/02/2001 | US6297260 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 10/02/2001 | US6297240 Particularly diseases caused by elevated intro-ocular pressure, such as ocular hypertension and glaucoma |
| 10/02/2001 | US6297238 3-aryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinases particularly tyrosine kinases and serine/threonine kinases |
| 10/02/2001 | US6297228 Use of angiostatic steroids in photodynamic therapy |
| 10/02/2001 | US6296851 For screening antibiotics |
| 09/27/2001 | WO2001071007A2 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF |
| 09/27/2001 | WO2001071005A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | WO2001071004A2 Proteases |
| 09/27/2001 | WO2001070945A1 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments |
| 09/27/2001 | WO2001070757A2 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | WO2001070748A1 THIEPINO [3,2-b] DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS |
| 09/27/2001 | WO2001070745A1 Pyranoindoles for treating glaucoma |
| 09/27/2001 | WO2001070742A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
| 09/27/2001 | WO2001070740A1 Process for preparing crystalline form i of cabergoline |
| 09/27/2001 | WO2001070738A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 09/27/2001 | WO2001070734A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | WO2001070732A1 Pyrazoline derivatives or tetrahydropyridazine derivatives and medicinal use thereof |
| 09/27/2001 | WO2001070729A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 09/27/2001 | WO2001070716A1 A process for the preparation of epothilone analogs and intermediates |
| 09/27/2001 | WO2001070705A1 2-acylaminobenzimidazole derivatives for treating glaucoma |
| 09/27/2001 | WO2001070702A1 6-hydroxy-indazole derivatives for treating glaucoma |
| 09/27/2001 | WO2001070701A1 5-hydroxy indazole derivatives for treating glaucoma |
| 09/27/2001 | WO2001070694A1 Amorphous torasemide modification |
| 09/27/2001 | WO2001070693A2 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 09/27/2001 | WO2001070673A2 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 09/27/2001 | WO2001070668A2 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | WO2001070662A2 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 09/27/2001 | WO2001070255A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 09/27/2001 | WO2001070233A2 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof |
| 09/27/2001 | WO2001070230A2 Compounds with 5-ht activity useful for controlling visual field loss |
| 09/27/2001 | WO2001070223A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma |
| 09/27/2001 | WO2001070222A2 Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 09/27/2001 | WO2001070207A2 5ht2 agonists for controlling iop and treating glaucoma |
| 09/27/2001 | WO2001062705A8 Aminoalcohol derivatives |
| 09/27/2001 | WO2001032654A3 Novel heterocyclic compounds and their use as medicines |
| 09/27/2001 | WO2001019829A3 Pyrazolopyrimidines as therapeutic agents |
| 09/27/2001 | WO2001019386A3 Composition for stabilizing corneal tissue during or after orthokeratology lens wear |
| 09/27/2001 | WO2001019320A3 Phospholipid prodrugs of anti-proliferative drugs |
| 09/27/2001 | WO2001012606B1 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 09/27/2001 | WO2001009178A3 Human chaperone proteins |
| 09/27/2001 | US20010025044 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 09/27/2001 | US20010025040 Useful for treating allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis; nonsedating antihistamines or salts, leukotriene D4 antagonist or 5-lipoxygenase inhibitor or FLAP protein antagonist |
| 09/27/2001 | US20010025024 Administering botulinum toxin |
| 09/27/2001 | US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2403823A1 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | CA2403808A1 Thiepino [3,2-b] dihydropyridines and related compositions and methods |
| 09/27/2001 | CA2403805A1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | CA2402836A1 Process for preparing crystalline form i of cabergoline |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402403A1 6-hydroxy-indazole derivatives for treating glaucoma |
| 09/27/2001 | CA2401969A1 5ht2 agonists for controlling iop and treating glaucoma |
| 09/27/2001 | CA2401959A1 5-hydroxy indazole derivatives for treating glaucoma |
| 09/27/2001 | CA2401908A1 Amorphous torasemide modification |
| 09/27/2001 | CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha. |
| 09/27/2001 | CA2401728A1 Difluorobutyric acid metalloprotease inhibitors |
| 09/27/2001 | CA2400637A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | CA2399991A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
| 09/27/2001 | CA2399985A1 Compounds with 5-ht activity useful for controlling visual field loss |
| 09/26/2001 | EP1136571A2 Detection of polymorphisms in the MxA gene to predict the response of an hepatitis C virus infected individual to interferon therapy |
| 09/26/2001 | EP1136503A1 Novel physiologically active substance, process for producing the same and utilization thereof |
| 09/26/2001 | EP1136488A1 Sf2809-i, ii, iii, iv, v and vi substances exhibiting chymase-inhibiting activities |
| 09/26/2001 | EP1136482A1 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| 09/26/2001 | EP1135688A2 Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| 09/26/2001 | EP1135498A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 09/26/2001 | EP1135477A1 Humanized monoclonal antibodies |
| 09/26/2001 | EP1135468A1 Virus vectors and methods of making and administering the same |
| 09/26/2001 | EP1135413A2 Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof |
| 09/26/2001 | EP1135377A1 Novel compounds |
| 09/26/2001 | EP1135374A1 Benzimidazole compounds that are vitronectin receptor antagonists |
| 09/26/2001 | EP1135159A2 Peptide-based vaccine for influenza |
| 09/26/2001 | EP1135151A1 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 09/26/2001 | EP1135135A1 Chk1 kinase inhibitors |
| 09/26/2001 | EP1135134A1 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
| 09/26/2001 | EP1135126A2 Myt1 kinase inhibitors |
| 09/26/2001 | EP1135123A1 Use of isatin derivatives as ion channel activating agents |
| 09/26/2001 | EP1135115A2 Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 09/26/2001 | EP1135105A2 Method for administering agents to the central nervous system |
| 09/26/2001 | EP0795326B1 Ocular tension depressant |
| 09/26/2001 | EP0738727B1 1,4-benzoxazine-2-acetic acid compound, process for producing the same, and use thereof |
| 09/26/2001 | CN1314810A Perfusate preparation for ophthalmic operation |
| 09/26/2001 | CN1071759C Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and use thereof |
| 09/25/2001 | US6294674 Dibenzofuran sulfonamide matrix metalloproteinase inhibitors |
| 09/25/2001 | US6294661 Compounds |
| 09/25/2001 | US6294652 Response regulator |
| 09/25/2001 | US6294564 Benzimidazoles and benzoxazoles |
| 09/25/2001 | US6294561 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/25/2001 | US6294556 Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 09/25/2001 | US6294553 Method for treating ocular pain |
| 09/25/2001 | US6294546 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 09/25/2001 | US6294538 Antidiabetic agents and diabetic neuropathy, treatment with oxidoreductase enzymes |
| 09/25/2001 | US6294525 Reverse-turn mimetics and methods relating thereto |
| 09/25/2001 | US6294517 Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| 09/25/2001 | US6294350 Methods for treating fibroproliferative diseases |
| 09/20/2001 | WO2001068860A1 Antibodies to human cd154 |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |